Effect of Alferon N on replication of influenza A viruses in cell cultures

Abstract

Influenza A virus is an important respiratory pathogen with the potential to affect both humans and animals, thereby creating the conditions for public health disasters, especially during pandemic episodes. At present, two primary strategies to combat influenza are vaccination and antiviral drugs. Since influenza viruses mutate rapidly and constantly via antigenic drift and shift, vaccines can become quickly outdated; and resistance to antiviral drugs can readily result. Interferon alpha (IFN-[alpha]) plays an important role as a first line of innate antiviral immunity. To investigate the antiviral potential of exogenously applied IFN-[alpha] on the replication of different subtypes of influenza A viruses, three subtypes of influenza A virus, i.e. swine H3N2, pandemic H1N1 and avian H9N2 were chosen. Their replication kinetics in the presence of Alferon N (human Interferon alpha) on human epithelium (A549) cells and swine testis (ST) cells was evaluated. In these tests of the three subtypes of influenza A viruses, it was found that the replication ability of all three viruses was inhibited when ST cells were treated with Alferon for four hours before infection. The ability of Alferon to inhibit influenza A viruses replication was found to be dose-dependent. Similar results were obtained when A549 cells were used; however, pretreatment of A549 cells with Alferon for more than 16 hours was necessary before infection. Furthermore, the expression of some ISGs (Interferon stimulated genes) between ST and A549 cells was also investigated. The differences in response of the ISGs between the two cell lines provided an explanation of the disparity towards exogenous interferon treatment. In summary, these results demonstrated that Alferon N has the ability to inhibit replication of different subtypes of influenza A viruses in cell cultures. This study provides a foundation for future in vivo studies using exogenous IFN-[alpha] treatment as an alternative approach to combat influenza A virus infection.